CIK: 0001687078 · Show all filings
Period: Q2 2025 (← Previous) (Next →)
Filing Date: Aug 14, 2025
Total Value ($000): $577,151 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | 7,648,268 | $57,591 | 10.0% | $40.60 | -80.2% | Common | 230031106 |
| MDGL | Madrigal Pharmaceuticals Inc | 100,415 | $30,390 | 5.3% | $328.59 | -9.3% | Common | 558868105 |
| ZLAB | Zai Lab Ltd | 745,060 | $26,055 | 4.5% | $26.59 | — | ADR | 98887Q104 |
| GH | Guardant Health Inc | 442,656 | $23,036 | 4.0% | $23.27 | +91.9% | Common | 40131M109 |
| SPRY | ARS Pharmaceuticals Inc | 1,303,399 | $22,744 | 3.9% | $12.03 | +19.9% | Common | 82835W108 |
| EWTX | Edgewise Therapeutics Inc | 1,720,741 | $22,559 | 3.9% | $17.71 | -18.6% | Common | 28036F105 |
| RNAM | Avidity Biosciences Inc | 760,022 | $21,585 | 3.7% | $39.95 | -25.4% | Common | 05370A108 |
| PTCT | PTC Therapeutics Inc | 438,477 | $21,415 | 3.7% | $40.98 | +15.8% | Common | 69366J200 |
| TRVI | Trevi Therapeutics Inc | 3,406,955 | $18,636 | 3.2% | $2.95 | +110.8% | Common | 89532M101 |
| ORIC | Oric Pharmaceuticals Inc | 1,729,378 | $17,553 | 3.0% | $8.36 | -19.7% | Common | 68622P109 |
| NTRA | Natera Inc | 98,924 | $16,712 | 2.9% | $76.08 | +104.8% | Common | 632307104 |
| ALKS | Alkermes Plc | 549,262 | $15,714 | 2.7% | $31.51 | -5.6% | Common | G01767105 |
| MLTX | Moonlake Immunotherapeutics | 313,571 | $14,801 | 2.6% | $29.33 | +38.9% | Class A Ord | 61559X104 |
| MBX | MBX Biosciences Inc | 1,294,416 | $14,769 | 2.6% | $10.53 | -3.2% | Common | 55287L101 |
| CMPX | Compass Therapeutics, Inc. | 5,622,505 | $14,619 | 2.5% | $1.57 | +31.0% | Common | 20454B104 |
| RARE | Ultragenyx Pharmaceutical Inc | 395,700 | $14,388 | 2.5% | $46.13 | -21.8% | Common | 90400D108 |
| JANX | Janux Therapeutics Inc | 614,282 | $14,190 | 2.5% | $39.90 | -34.0% | Common | 47103J105 |
| TARS | Tarsus Pharmaceuticals Inc | 341,496 | $13,834 | 2.4% | $45.00 | 0.0% | Common | 87650L103 |
| DYN | Dyne Therapeutics, Inc. | 1,446,361 | $13,769 | 2.4% | $11.01 | 0.0% | Common | 26818M108 |
| VERA | Vera Therapeutics Inc. | 563,075 | $13,266 | 2.3% | $35.17 | -36.1% | Class A Ord | 92337R101 |
| CRNX | Crinetics Pharmaceuticals Inc. | 428,975 | $12,337 | 2.1% | $29.47 | +4.8% | Common | 22663K107 |
| RVMD | Revolution Medicines, Inc. | 315,722 | $11,615 | 2.0% | $29.31 | +31.1% | Common | 76155X100 |
| AKBA | Akebia Therapeutics Inc | 2,889,125 | $10,516 | 1.8% | $2.75 | 0.0% | Common | 00972D105 |
| OLMA | Olema Pharmaceuticals, Inc. | 2,378,762 | $10,134 | 1.8% | $9.76 | -54.3% | Common | 68062P106 |
| XENE | Xenon Pharmaceuticals Inc | 323,398 | $10,122 | 1.8% | $39.17 | -16.7% | Common | 98420N105 |
| WVE | Wave Life Sciences PTE LTD | 1,505,262 | $9,784 | 1.7% | $10.27 | -35.7% | Common | Y95308105 |
| DBVT | DBV Technologies S A | 1,054,504 | $9,649 | 1.7% | $9.15 | — | SPONSORED ADS | 23306J309 |
| CNTX | Context Therapeutics Inc | 14,705,882 | $9,635 | 1.7% | $1.73 | -58.5% | Common | 21077P108 |
| RCKT | Rocket Pharmaceuticals, Inc. | 3,903,081 | $9,563 | 1.7% | $9.83 | -48.5% | Common | 77313F106 |
| REPL | Replimune Group Inc | 983,780 | $9,139 | 1.6% | $12.16 | -28.2% | Common | 76029N106 |
| NUVB | Nuvation Bio Inc | 4,622,590 | $9,014 | 1.6% | $2.54 | -18.1% | Common | 67080N101 |
| STOK | Stoke Therapeutics Inc | 789,698 | $8,963 | 1.6% | $13.06 | -27.3% | Common | 86150R107 |
| SLDB | Solid Biosciences Inc | 1,634,569 | $7,960 | 1.4% | $4.28 | -17.4% | Common | 83422E204 |
| RLAY | Relay Therapeutics Inc. | 2,282,680 | $7,898 | 1.4% | $10.70 | -72.2% | Common | 75943R102 |
| RNAC | Cartesian Therapeutics Inc | 686,007 | $7,128 | 1.2% | $19.06 | -44.1% | Common | 816212302 |
| TSHA | Taysha Gene Therapies, Inc. | 2,953,562 | $6,823 | 1.2% | $2.17 | 0.0% | Common | 877619106 |
| SRPT | Sarepta Therapeutics Inc | 321,696 | $5,501 | 1.0% | $42.66 | 0.0% | Common | 803607100 |
| SLNO | Soleno Therapeutics Inc | 50,000 | $4,189 | 0.7% | $74.85 | 0.0% | Common | 834203309 |
| — | Veru Inc. | 4,911,948 | $2,858 | 0.5% | $0.59 | — | Common | 92536C103 |
| HOWL | Werewolf Therapeutics, Inc. | 2,408,810 | $2,626 | 0.5% | $13.70 | -92.5% | Common | 95075A107 |
| DSGN | Design Therapeutics Inc | 555,187 | $1,871 | 0.3% | $5.79 | -35.4% | Common | 25056L103 |
| — | Repare Therapeutics, Inc. | 819,924 | $1,140 | 0.2% | $31.02 | — | Common | 760273102 |
| ADAPY | Adaptimmune Therapeutics plc | 4,411,821 | $1,058 | 0.2% | $0.93 | — | Sponsored ADS | 00653A107 |
| ACLX | Arcellx Inc | 37 | $2 | 0.0% | $62.26 | 0.0% | Common | 03940C100 |